Cargando…

VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient

BACKGROUND: Biologic specificity of diffusion MRI in relation to prostate cancer aggressiveness may improve by examining separate components of the diffusion MRI signal. The Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumors (VERDICT) model estimates three distinct signal comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Edward W., Bonet-Carne, Elisenda, Ferizi, Uran, Yvernault, Ben, Pye, Hayley, Patel, Dominic, Clemente, Joey, Piga, Wivijin, Heavey, Susan, Sidhu, Harbir S., Giganti, Francesco, O’Callaghan, James, Brizmohun Appayya, Mrishta, Grey, Alistair, Saborowska, Alexandra, Ourselin, Sebastien, Hawkes, David, Moore, Caroline M., Emberton, Mark, Ahmed, Hashim U., Whitaker, Hayley, Rodriguez-Justo, Manuel, Freeman, Alexander, Atkinson, David, Alexander, Daniel, Panagiotaki, Eleftheria, Punwani, Shonit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radiological Society of North America 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493214/
https://www.ncbi.nlm.nih.gov/pubmed/30938627
http://dx.doi.org/10.1148/radiol.2019181749
_version_ 1783415174868238336
author Johnston, Edward W.
Bonet-Carne, Elisenda
Ferizi, Uran
Yvernault, Ben
Pye, Hayley
Patel, Dominic
Clemente, Joey
Piga, Wivijin
Heavey, Susan
Sidhu, Harbir S.
Giganti, Francesco
O’Callaghan, James
Brizmohun Appayya, Mrishta
Grey, Alistair
Saborowska, Alexandra
Ourselin, Sebastien
Hawkes, David
Moore, Caroline M.
Emberton, Mark
Ahmed, Hashim U.
Whitaker, Hayley
Rodriguez-Justo, Manuel
Freeman, Alexander
Atkinson, David
Alexander, Daniel
Panagiotaki, Eleftheria
Punwani, Shonit
author_facet Johnston, Edward W.
Bonet-Carne, Elisenda
Ferizi, Uran
Yvernault, Ben
Pye, Hayley
Patel, Dominic
Clemente, Joey
Piga, Wivijin
Heavey, Susan
Sidhu, Harbir S.
Giganti, Francesco
O’Callaghan, James
Brizmohun Appayya, Mrishta
Grey, Alistair
Saborowska, Alexandra
Ourselin, Sebastien
Hawkes, David
Moore, Caroline M.
Emberton, Mark
Ahmed, Hashim U.
Whitaker, Hayley
Rodriguez-Justo, Manuel
Freeman, Alexander
Atkinson, David
Alexander, Daniel
Panagiotaki, Eleftheria
Punwani, Shonit
author_sort Johnston, Edward W.
collection PubMed
description BACKGROUND: Biologic specificity of diffusion MRI in relation to prostate cancer aggressiveness may improve by examining separate components of the diffusion MRI signal. The Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumors (VERDICT) model estimates three distinct signal components and associates them to (a) intracellular water, (b) water in the extracellular extravascular space, and (c) water in the microvasculature. PURPOSE: To evaluate the repeatability, image quality, and diagnostic utility of intracellular volume fraction (FIC) maps obtained with VERDICT prostate MRI and to compare those maps with apparent diffusion coefficient (ADC) maps for Gleason grade differentiation. MATERIALS AND METHODS: Seventy men (median age, 62.2 years; range, 49.5–82.0 years) suspected of having prostate cancer or undergoing active surveillance were recruited to a prospective study between April 2016 and October 2017. All men underwent multiparametric prostate and VERDICT MRI. Forty-two of the 70 men (median age, 67.7 years; range, 50.0–82.0 years) underwent two VERDICT MRI acquisitions to assess repeatability of FIC measurements obtained with VERDICT MRI. Repeatability was measured with use of intraclass correlation coefficients (ICCs). The image quality of FIC and ADC maps was independently evaluated by two board-certified radiologists. Forty-two men (median age, 64.8 years; range, 49.5–79.6 years) underwent targeted biopsy, which enabled comparison of FIC and ADC metrics in the differentiation between Gleason grades. RESULTS: VERDICT MRI FIC demonstrated ICCs of 0.87–0.95. There was no significant difference between image quality of ADC and FIC maps (score, 3.1 vs 3.3, respectively; P = .90). FIC was higher in lesions with a Gleason grade of at least 3+4 compared with benign and/or Gleason grade 3+3 lesions (mean, 0.49 ± 0.17 vs 0.31 ± 0.12, respectively; P = .002). The difference in ADC between these groups did not reach statistical significance (mean, 1.42 vs 1.16 × 10(-3) mm(2)/sec; P = .26). CONCLUSION: Fractional intracellular volume demonstrates high repeatability and image quality and enables better differentiation of a Gleason 4 component cancer from benign and/or Gleason 3+3 histology than apparent diffusion coefficient. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Sigmund and Rosenkrantz in this issue.
format Online
Article
Text
id pubmed-6493214
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Radiological Society of North America
record_format MEDLINE/PubMed
spelling pubmed-64932142020-01-28 VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient Johnston, Edward W. Bonet-Carne, Elisenda Ferizi, Uran Yvernault, Ben Pye, Hayley Patel, Dominic Clemente, Joey Piga, Wivijin Heavey, Susan Sidhu, Harbir S. Giganti, Francesco O’Callaghan, James Brizmohun Appayya, Mrishta Grey, Alistair Saborowska, Alexandra Ourselin, Sebastien Hawkes, David Moore, Caroline M. Emberton, Mark Ahmed, Hashim U. Whitaker, Hayley Rodriguez-Justo, Manuel Freeman, Alexander Atkinson, David Alexander, Daniel Panagiotaki, Eleftheria Punwani, Shonit Radiology Original Research BACKGROUND: Biologic specificity of diffusion MRI in relation to prostate cancer aggressiveness may improve by examining separate components of the diffusion MRI signal. The Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumors (VERDICT) model estimates three distinct signal components and associates them to (a) intracellular water, (b) water in the extracellular extravascular space, and (c) water in the microvasculature. PURPOSE: To evaluate the repeatability, image quality, and diagnostic utility of intracellular volume fraction (FIC) maps obtained with VERDICT prostate MRI and to compare those maps with apparent diffusion coefficient (ADC) maps for Gleason grade differentiation. MATERIALS AND METHODS: Seventy men (median age, 62.2 years; range, 49.5–82.0 years) suspected of having prostate cancer or undergoing active surveillance were recruited to a prospective study between April 2016 and October 2017. All men underwent multiparametric prostate and VERDICT MRI. Forty-two of the 70 men (median age, 67.7 years; range, 50.0–82.0 years) underwent two VERDICT MRI acquisitions to assess repeatability of FIC measurements obtained with VERDICT MRI. Repeatability was measured with use of intraclass correlation coefficients (ICCs). The image quality of FIC and ADC maps was independently evaluated by two board-certified radiologists. Forty-two men (median age, 64.8 years; range, 49.5–79.6 years) underwent targeted biopsy, which enabled comparison of FIC and ADC metrics in the differentiation between Gleason grades. RESULTS: VERDICT MRI FIC demonstrated ICCs of 0.87–0.95. There was no significant difference between image quality of ADC and FIC maps (score, 3.1 vs 3.3, respectively; P = .90). FIC was higher in lesions with a Gleason grade of at least 3+4 compared with benign and/or Gleason grade 3+3 lesions (mean, 0.49 ± 0.17 vs 0.31 ± 0.12, respectively; P = .002). The difference in ADC between these groups did not reach statistical significance (mean, 1.42 vs 1.16 × 10(-3) mm(2)/sec; P = .26). CONCLUSION: Fractional intracellular volume demonstrates high repeatability and image quality and enables better differentiation of a Gleason 4 component cancer from benign and/or Gleason 3+3 histology than apparent diffusion coefficient. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Sigmund and Rosenkrantz in this issue. Radiological Society of North America 2019-05 2019-04-02 /pmc/articles/PMC6493214/ /pubmed/30938627 http://dx.doi.org/10.1148/radiol.2019181749 Text en 2019 by the Radiological Society of North America, Inc. http://creativecommons.org/licenses/by/4.0/ Published under a (http://creativecommons.org/licenses/by/4.0/) CC BY 4.0 license.
spellingShingle Original Research
Johnston, Edward W.
Bonet-Carne, Elisenda
Ferizi, Uran
Yvernault, Ben
Pye, Hayley
Patel, Dominic
Clemente, Joey
Piga, Wivijin
Heavey, Susan
Sidhu, Harbir S.
Giganti, Francesco
O’Callaghan, James
Brizmohun Appayya, Mrishta
Grey, Alistair
Saborowska, Alexandra
Ourselin, Sebastien
Hawkes, David
Moore, Caroline M.
Emberton, Mark
Ahmed, Hashim U.
Whitaker, Hayley
Rodriguez-Justo, Manuel
Freeman, Alexander
Atkinson, David
Alexander, Daniel
Panagiotaki, Eleftheria
Punwani, Shonit
VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient
title VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient
title_full VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient
title_fullStr VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient
title_full_unstemmed VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient
title_short VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient
title_sort verdict mri for prostate cancer: intracellular volume fraction versus apparent diffusion coefficient
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493214/
https://www.ncbi.nlm.nih.gov/pubmed/30938627
http://dx.doi.org/10.1148/radiol.2019181749
work_keys_str_mv AT johnstonedwardw verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT bonetcarneelisenda verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT feriziuran verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT yvernaultben verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT pyehayley verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT pateldominic verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT clementejoey verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT pigawivijin verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT heaveysusan verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT sidhuharbirs verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT gigantifrancesco verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT ocallaghanjames verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT brizmohunappayyamrishta verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT greyalistair verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT saborowskaalexandra verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT ourselinsebastien verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT hawkesdavid verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT moorecarolinem verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT embertonmark verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT ahmedhashimu verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT whitakerhayley verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT rodriguezjustomanuel verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT freemanalexander verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT atkinsondavid verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT alexanderdaniel verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT panagiotakieleftheria verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient
AT punwanishonit verdictmriforprostatecancerintracellularvolumefractionversusapparentdiffusioncoefficient